PURPOSE: Non-invasive encapsulated follicular variant of papillary thyroid cancer was reclassified as non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP). These neoplasms have an extremely low malignant potential. The aim of this study was (1) to assess the prevalence of NIFTP in patients with papillary thyroid carcinoma, (2) to evaluate their outcomes, and (3) to determine their molecular profile. METHODS: Multicenter, descriptive, retrospective study. Patients with papillary thyroid cancer diagnosed from January 2006 to December 2016 from 11 referral centers were included. Diagnosis of NIFTP was based on criteria described by Nikiforov et al. in 2018. At least two pathologists agreed on the diagnosis. Two thousand six hundred and seventy-seven papillary thyroid cancer patients were included; 456 (17%) of them were follicular variant papillary thyroid cancer, and 30 (1.12%) fulfilled diagnostic criteria for NIFTP. RESULTS: Each of the 30 included patients underwent a total thyroidectomy, and 50% were treated with radioiodine (median dose 100 mCi). After a median follow-up of 37 months, 84% of patients had an excellent response, 3% had an indeterminate response and data was missing in the remaining 13%. No metastatic lymph nodes, distant metastases or recurrences were found. RAS mutations were detected in 4 patients (13%). CONCLUSION: The prevalence of NIFTP in our series is amongst the lowest reported. Excellent outcomes of patients underscore their low malignant potential. Molecular findings differ from other series, probably related to environmental or ethnic features of our population and the meticulous criteria for diagnosing NIFTP.
PURPOSE: Non-invasive encapsulated follicular variant of papillary thyroid cancer was reclassified as non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP). These neoplasms have an extremely low malignant potential. The aim of this study was (1) to assess the prevalence of NIFTP in patients with papillary thyroid carcinoma, (2) to evaluate their outcomes, and (3) to determine their molecular profile. METHODS: Multicenter, descriptive, retrospective study. Patients with papillary thyroid cancer diagnosed from January 2006 to December 2016 from 11 referral centers were included. Diagnosis of NIFTP was based on criteria described by Nikiforov et al. in 2018. At least two pathologists agreed on the diagnosis. Two thousand six hundred and seventy-seven papillary thyroid cancer patients were included; 456 (17%) of them were follicular variant papillary thyroid cancer, and 30 (1.12%) fulfilled diagnostic criteria for NIFTP. RESULTS: Each of the 30 included patients underwent a total thyroidectomy, and 50% were treated with radioiodine (median dose 100 mCi). After a median follow-up of 37 months, 84% of patients had an excellent response, 3% had an indeterminate response and data was missing in the remaining 13%. No metastatic lymph nodes, distant metastases or recurrences were found. RAS mutations were detected in 4 patients (13%). CONCLUSION: The prevalence of NIFTP in our series is amongst the lowest reported. Excellent outcomes of patients underscore their low malignant potential. Molecular findings differ from other series, probably related to environmental or ethnic features of our population and the meticulous criteria for diagnosing NIFTP.
Authors: Miguel Paja; Carles Zafón; Carmela Iglesias; Aitziber Ugalde; Jose Manuel Cameselle-Teijeiro; Gemma Rodríguez-Carnero; Pilar Fernández-Seara; Emma Anda; Antónia Povoa; Hernán Quiceno; Nancy M Sánchez-Gómez; Clarisa González; Luis García-Pascual; Inés Gómez de la Riva; Concha Blanco; Telma Meizoso; Garcilaso Riesco-Eizaguirre; Ismael Capel; María Victoria Ortega; Isabel Mancha; Montserrat Chao; Victoria Alcázar; Esther Roselló; Javier Maravall; Susana López-Agulló; Antonia Pérez-Lázaro; Pascual Meseguer; Javier Sanz; Jose J Paricio; Saioa Echeverría; Ángel Castaño; Rosa M Bella Journal: Endocrine Date: 2021-01-23 Impact factor: 3.633
Authors: Yuri E Nikiforov; Zubair W Baloch; Steven P Hodak; Thomas J Giordano; Ricardo V Lloyd; Raja R Seethala; Bruce M Wenig Journal: JAMA Oncol Date: 2018-08-01 Impact factor: 31.777
Authors: Yuri E Nikiforov; Raja R Seethala; Giovanni Tallini; Zubair W Baloch; Fulvio Basolo; Lester D R Thompson; Justine A Barletta; Bruce M Wenig; Abir Al Ghuzlan; Kennichi Kakudo; Thomas J Giordano; Venancio A Alves; Elham Khanafshar; Sylvia L Asa; Adel K El-Naggar; William E Gooding; Steven P Hodak; Ricardo V Lloyd; Guy Maytal; Ozgur Mete; Marina N Nikiforova; Vania Nosé; Mauro Papotti; David N Poller; Peter M Sadow; Arthur S Tischler; R Michael Tuttle; Kathryn B Wall; Virginia A LiVolsi; Gregory W Randolph; Ronald A Ghossein Journal: JAMA Oncol Date: 2016-08-01 Impact factor: 31.777
Authors: David N Parente; Pim J Bongers; Raoul Verzijl; Lorne E Rotstein; Sylvia L Asa; Wouter P Kluijfhout; Karen M Devon; David P Goldstein; Ozgur Mete; Jesse D Pasternak Journal: World J Surg Date: 2018-07 Impact factor: 3.352
Authors: Robert L Ferris; Yuri Nikiforov; Davis Terris; Raja R Seethala; J Andrew Ridge; Peter Angelos; Quan-Yang Duh; Richard Wong; Mona M Sabra; James A Fagin; Bryan McIver; Victor J Bernet; R Mack Harrell; Naifa Busaidy; Edmund S Cibas; William C Faquin; Peter Sadow; Zubair Baloch; Maisie Shindo; Lisa Orloff; Louise Davies; Gregory W Randolph Journal: Head Neck Date: 2018-06-26 Impact factor: 3.147
Authors: Hyereen Kim; Bo Hyun Kim; Young Keum Kim; Jeong Mi Kim; Seo Young Oh; Eun Heui Kim; Min Jin Lee; Jong Ho Kim; Yun Kyung Jeon; Sang Soo Kim; Byung Joo Lee; Yong Ki Kim; In Joo Kim Journal: J Korean Med Sci Date: 2018-01-24 Impact factor: 2.153